Alnylam Pharmaceuticals, Inc. (ALNY) Analyst Ratings & Price Targets

Alnylam Pharmaceuticals, Inc.

ALNY · Nasdaq

Analyst Consensus

Buy

26 analysts

$250

Current

$357

Low

$354

Average

$357

High

Average target implies +41.46% versus the current price.

Analyst Ratings Synthesis

Consensus remains Buy across 26 analysts, with a mean target of $375; the supplied consensus does not provide low or high targets. A separate Investing.com compilation of 25 analysts places targets between $310 and $566, indicating a wide spread rather than a tight cluster. The evidence does not identify the current most- or least-bullish analyst, although Truist Securities previously cited a $505 target and Needham previously maintained Buy at $357. Revision evidence is directionally lower: Simply Wall St says the updated target moved to $305.63 from $320.21. The substantive disagreement is whether AMVUTTRA’s strong growth and improving profitability outweigh the TTR guidance cut and competitive ATTR-CM risks.

Rating Actions

2 firms captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Raymond James	—	Strong Buy Upgraded	—	—	Aug 3, 2026	Open the report this row came from
Needham	Joseph Stringer	Buy Maintained Buy and lowered price target	$357from $510	+42.9%	Oct 5, 2023	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BARCLAYS CAPITA

BMO CAPITAL MKT

CANACCORD GENUI

CANTOR FITZGERA

CHARDAN CAPITAL

CITIGROUP

EVERCORE ISI

GOLDMAN SACHS

GUGGENHEIM SEC.

H C WAINWRIGHT

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

NEEDHAM & CO.

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

WELLS FARGO SEC

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: ALNY
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: Nasdaq

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health.

Key Issues

Bullish view

AMVUTTRA continued to gain traction, driving approximately $1.2 billion of second-quarter global net product revenue and 74% year-over-year growth. Strong uptake could eventually outweigh the reduced full-year TTR sales outlook.

Bearish view

Management’s 2026 TTR product-sales guidance reduction indicates that near-term demand or execution is weaker than investors expected. The guidance cut dominated the quarter despite record AMVUTTRA sales.

Analyst Consensus

See all

Buy

26 analysts

$250

Current

$357

Low

$354

Average

$357

High

Average target implies +41.46% versus the current price.

Earnings History

BeatMissNo estimate

Alnylam Pharmaceuticals, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers